We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
More than a year after shutting down its CAR-T trial after subjects died, Juno Therapeutics agreed to pay $24 million to investors who claimed they were not properly informed. Read More
Three national foundations have committed $30 million to the launch of a not-for-profit generic drug company — first announced in January — citing the rising prices of generics and the risks patients face from drug shortages. Read More
Maryland’s Attorney General filed charges against Insys Therapeutics over alleged violations of the state’s Consumer Protection Act, saying the company joined local health care providers in an “unfair and deceptive scheme” to promote its breakthrough pain drug Subsys. Read More
The letter follows an April Senate Finance Committee hearing during which a senior HHS official testified the department had not pressed drugmakers on why they hiked the price of naloxone. Read More
In a new attempt to prod action by HHS to lower the price of the opioid-reversing drug naloxone, Sen. Claire McCaskill (D-Mo.) asked HHS Secretary Alex Azar what the department has done since she grilled another HHS official on the issue earlier this year. Read More
A Massachusetts court Wednesday ruled in favor of Janssen in a lawsuit that claimed the Johnson and Johnson subsidiary’s antipsychotic Risperdal (risperidone) caused excessive weight gain. Read More
The Senate this week unanimously passed legislation that would forbid insurers and pharmacy benefit managers from imposing “gag clauses” on drug prices. Read More
“In order to make medicines more affordable for patients, we must address the role hospital markups play in driving up medicine costs,” said PhRMA CEO Stephen Ubl. Read More